STOCK TITAN

AN2 officer sells 272 shares at $5.53

AN2 Therapeutics, Inc. (ANTX) reported that Principal Accounting Officer Sarah Joanne Williams sold 272 shares of common stock on September 1, 2026 at $5.53 per share.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. (ANTX) reported that Principal Accounting Officer Sarah Joanne Williams sold 272 shares of common stock on September 1, 2026 at $5.53 per share. The sale was made pursuant to the grant terms to satisfy tax withholding obligations arising from RSU vesting on August 28, 2026.

After this transaction, Williams holds 66,311 shares directly, including RSUs that vest through 2029, subject to her continuous service. No Rule 10b5-1 trading plan is reported for this sale.

Positive

  • None.

Negative

  • None.
Insider Williams Sarah Joanne
Role Principal Accounting Officer
Sold 272 shs ($2K)
Type Security Shares Price Value
Sale Common Stock F1, F2 272 $5.53 $2K
Holdings After Transaction: Common Stock — 66,311 shares (Direct)
Footnotes (2)
  1. F1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on August 28, 2026.
  2. F2. Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 4,038 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market.
Shares sold 272 shares Common stock sale on September 1, 2026 to satisfy tax withholding
Sale price $5.53 per share Common stock sold on September 1, 2026
Shares held after transaction 66,311 shares Direct holdings after September 1, 2026 sale
RSU grant (a) 48,375 RSUs Vest annually over four years from January 1, 2026
RSU grant (b) 10,938 RSUs Vest annually over four years from January 1, 2025
RSU grant (c) 11,850 RSUs Vest quarterly over four years from May 28, 2024
Shares sold to cover taxes 4,038 shares From RSU grants (b) and (c) sold to cover tax obligations
Shares sold on open market 814 shares Shares from RSU grants (b) and (c) sold on the open market
Restricted Stock Units financial
"arising from the vesting of Restricted Stock Units ("RSUs") on August 28, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"shares sold pursuant to the terms of the grant to satisfy tax withholding obligations"
continuous service financial
"in each case subject to the Reporting Person's continuous service through each applicable vesting date"
vesting financial
"RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What insider transaction did ANTX report for Sarah Joanne Williams?

ANTX reported that Principal Accounting Officer Sarah Joanne Williams sold 272 shares of common stock on September 1, 2026 at $5.53 per share, to satisfy tax withholding obligations from RSU vesting on August 28, 2026.

How many ANTX shares does Sarah Joanne Williams hold after this Form 4 transaction?

After the reported sale, Sarah Joanne Williams holds 66,311 shares of ANTX common stock directly, which includes multiple RSU awards that continue to vest over several years, subject to her continuous service.

Were the ANTX shares sold by Sarah Joanne Williams part of a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 trading plan for this transaction; the shares were sold under the grant terms to cover tax withholding from vested RSUs.

What RSU awards in ANTX does Sarah Joanne Williams have outstanding?

Her holdings include 48,375 RSUs vesting over four years from January 1, 2026, 10,938 RSUs vesting over four years from January 1, 2025, and 11,850 RSUs vesting quarterly over four years from May 28, 2024, subject to continuous service.

How many ANTX shares tied to RSUs have been sold for taxes or on the open market?

The filing states that a total of 4,038 shares from certain RSU grants were sold to cover taxes and a total of 814 shares were sold on the open market, in connection with those RSU awards.

What is the significance of the ANTX RSU vesting conditions for Sarah Joanne Williams?

Each ANTX RSU grant vests in installments over four years and is subject to Williams’s continuous service through each vesting date, meaning unvested RSUs depend on her remaining with the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Williams Sarah Joanne

(Last)(First)(Middle)
C/O AN2 THERAPEUTICS, INC.
1300 EL CAMINO REAL, SUITE 100

(Street)
MENLO PARK CALIFORNIA 94025

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Principal Accounting Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/01/2026S272(1)D$5.5366,311(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on August 28, 2026.
2. Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 4,038 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market.
/s/ Sarah Joanne Williams09/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading